AU Patent

AU2023321459A1 — Composition of piperazine compound and pd-1 inhibitor or pd-l1 inhibitor and use thereof in treating tumors

Assigned to Kangbaida Sichuan Biotechnology Co Ltd · Expires 2025-02-13 · 1y expired

What this patent protects

The present application relates to a combination of a piperazine compound and a PD-1 inhibitor antibody or a PD-L1 inhibitor antibody and use thereof in treating tumors.

USPTO Abstract

The present application relates to a combination of a piperazine compound and a PD-1 inhibitor antibody or a PD-L1 inhibitor antibody and use thereof in treating tumors.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023321459A1
Jurisdiction
AU
Classification
—
Expires
2025-02-13
Drug substance claim
No
Drug product claim
No
Assignee
Kangbaida Sichuan Biotechnology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.